BioNTech
€74.45
1405
-€1.5-1.97% Friday 17:44
Estatísticas
Ponto mais alto do dia
75.2
Ponto mais baixo do dia
73.45
Ponto mais alto em 52 semanas
-
Ponto mais baixo em 52 semanas
-
Volume
302
Volume méd.
-
Limite da capitalização de mercado
18.15B
Rácio PER
160.21
Rendimento de dividendos
-
Dividendo
-
Dividendos
0%Rendimento de dividendos
Crescimento a 10 anos
N/D
Crescimento a 5 anos
N/D
Crescimento a 3 anos
N/D
Crescimento a 1 ano
N/D
Rendimentos
6MayConfirmado
Resultados por ação esperados
-1.17
Resultados por ação reais
-1.42
As pessoas também seguem
Esta lista baseia-se nas listas de observação de pessoas na Stock Events que seguem 22UA.F. Não é uma recomendação de investimento.
Concorrentes
Esta lista é uma análise baseada em eventos recentes do mercado. Não é uma recomendação de investimento.
Moderna
MRNA
Limite da capitalização de mercado45.51B
Pfizer
PFE
Limite da capitalização de mercado158.55B
Novavax
NVAX
Limite da capitalização de mercado1.78B
Johnson & Johnson
JNJ
Limite da capitalização de mercado351.76B
Astrazeneca
AZN
Limite da capitalização de mercado241.81B
Sanofi
SNY
Limite da capitalização de mercado122.89B
GSK
GSK
Limite da capitalização de mercado79.79B
Arcturus Therapeutics
ARCT
Limite da capitalização de mercado655.79M
Incyte
INCY
Limite da capitalização de mercado13.61B
Sobre
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac
Show more...
CEO
Dr. Ugur Sahin M.D.
Funcionários
6133
País
US
ISIN
US09075V1026
WKN
000A2PSR2